Expertise in
16
conditions

Diego C. Centonze

Via Atinense 18, IS, 
Pozzilli, IT 
Expertise in
16
conditions
Via Atinense 18, IS, 
Pozzilli, IT 
OverviewLocationsClinical Research

Overview

Diego Centonze practices in Pozzilli, Italy. Mr. Centonze is highly rated in 16 conditions, according to our data. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Relapsing Multiple Sclerosis (RMS), Spasticity, and Deep Brain Stimulation.

His clinical research consists of co-authoring 427 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Via Atinense 18, IS, Pozzilli, 86077, Italy
Other Locations
Is, Pozzilli, Italy
Is, Pozzilli, 86077, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
View 1 Less Clinical Trial

427 Total Publications

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
Journal: Neurology
Published: July 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Centonze's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 36 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile